Biliary Rhabdomyosarcoma in an Infant Male With Neurofibromatosis Type 1.

J Pediatr Hematol Oncol

Departments of Pediatrics, Division of Pediatric Hematology-Oncology.

Published: January 2019

Different types of malignancies can be seen in patients with neurofibromatosis type 1 (NF-1). Herein we present a rare combination of NF-1 and biliary rhabdomyosarcoma in a male infant. An 11-month-old boy, who was recently diagnosed with NF-1, presented to the outpatient clinic with a 3-month history of prolonged jaundice, and failure to thrive. Clinical examination showed >20 café au let spots distributed mainly over the abdominal trunk. Hepatomegaly (4 cm below the costal margin) was additionally observed. His father was diagnosed with NF-1. Radiologic imaging studies showed a 6×5×5 cm in diameter cystic mass with multiple septations in the segment 4A of the liver. Surgical excision of the left hepatic lobe followed by hepatojejunostomy was further performed. Histopathology examination showed embryonal type rhabdomyosarcoma originating from the biliary duct. Chemotherapy regimen consisting of cyclophosphamide, actinomycin D, and vincristine, and radiotherapy were then initiated. This treatment led to a significant improvement in the patient's clinical status, and radiologic finding portrayed attainment of complete resolution. He is still in complete remission without any sequelae for 8 years.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001163DOI Listing

Publication Analysis

Top Keywords

biliary rhabdomyosarcoma
8
neurofibromatosis type
8
diagnosed nf-1
8
rhabdomyosarcoma infant
4
infant male
4
male neurofibromatosis
4
type types
4
types malignancies
4
malignancies patients
4
patients neurofibromatosis
4

Similar Publications

The Other Site of Rhabdomyosarcoma.

Cancer Med

October 2024

Department of Pediatric Hematology and Oncology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Background: Rhabdomyosarcoma (RMS) is a rare malignant soft tissue sarcoma (STS), accounting for almost 50% of pediatric STSs. Due to its heterogeneity, RMS presents challenges in diagnosis and treatment, with prognosis varying depending on multiple factors. Tumors localized in the other site (OTH)-including the paraspinal, perianal, thoracic, abdominal, pelvic, and perineal regions-are generally classified as unfavorable.

View Article and Find Full Text PDF

Space-making particle therapy, which consists of surgical placement of a spacer followed by particle therapy, has become a solution to the problem of normal organs being exposed to a high radiation dose. A bioabsorbable spacer is particularly suitable for this purpose, but is not widely used. Surgical placement of a spacer is performed mostly to protect the digestive tract, but can also be used to protect the kidneys.

View Article and Find Full Text PDF
Article Synopsis
  • Gallbladder cancer (GBC) is a highly aggressive cancer with a poor prognosis, often diagnosed at advanced stages, and current treatments are limited and ineffective.
  • The study investigates the role of bromodomain-containing protein 9 (BRD9) in GBC, revealing that higher levels of BRD9 are linked to worse patient outcomes and decreased cell growth when suppressed.
  • Targeting BRD9 with the inhibitor I-BRD9 shows potential in reducing GBC cell proliferation and may serve as a promising biomarker and therapeutic target.
View Article and Find Full Text PDF
Article Synopsis
  • Rhabdomyosarcoma (RMS) of the biliary tract is a rare pediatric cancer, accounting for only 0.5-0.8% of all RMS cases in children, yet it is the most common malignancy in this area for that age group.
  • The study analyzed the medical records of eight children treated for biliary tract RMS between 1996-2022, focusing on symptoms, diagnoses, treatment approaches, and outcomes.
  • Among the patients, initial symptoms included jaundice, with treatment involving biopsy, chemotherapy, and surgery; 75% of the patients are currently alive with no disease progression after a median follow-up of over 11 years.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!